Several studies have shown that plicamycin can effectively target the activity of SP-1 protein on the SETDB1 promoter to inhibit SETDB1 expression, thus offering a beneficial therapeutic strategy for melanoma (Federico et al., 2020). Here, SP1 is linked to melanoma.